- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02623764
EEG-cholinergic Index and Clinical Response to Treatment With Cholinesterase Inhibitors (Cholindex)
EEG-cholinergic Index and Its Validation of Clinical Response to Treatment With Cholinesterase Inhibitors
Study Overview
Status
Conditions
Detailed Description
Patients will be recruited in a Memory Clinic. Three possible groups of participants will be offered participation:
- Those with Mild Cognitive Impairment (MCI) but with biomarkers of Alzheimer´s disease (AD) that are conclusive enough to lead to the diagnosis of AD and to initiate medical treatment.
- Those with early dementia of AD that are offered medical treatment and are able to give consent.
- Those with early dementia of Lewy body dementia or Parkinson dementia that are offered medical treatment.
All eligible participants are evaluated by the Mini Mental State Examination (MMSE), Consortium to Establish Registry in Alzheimer´s Disease (CERAD 10 word test; working memory, delayed memory and recognition) and Clock Drawing Test (CDT). In addition, the Addenbrooke test will be used.
Patients with AD irrespective of stage will be offered treatment with donepezil, the most used and cheapest cholinesterase inhibitor in Iceland. The dosis will be as usual, 5mg in the evening for four weeks, then increased to 10mg in the evening.
Patients with Lewy body dementia and Parkinson dementia are offered rivastigmine in patch as this is the only medication with the indication of cognitive impairment in these disorders. The starting dose is 4.6mg/day increased to 9.5mg/day after 4 weeks.
After 3 months, each participant is evaluated again with the same tests as before initiating treatment (continuous variables). The clinical effect is also rated according to Clinical Dementia Rating (CDR; categorical variables). An EEG registration is performed. Adherence to drug therapy as well as evaluation of side effects is registrated.
After 6 months, each participant is evaluated again as after 3 months. This is the primary end point.
After 12 months an additional evaluation is performed by the same instruments (secondary endpoint).
The EEG is thus registrated 3 times (primary end point) or 4 times (secondary end point as the first registration was done during the diagnostic work up before entering the project. The EEG will reveal group wise category (Normal, AD or Lewy according to the third edition (SIGLA) of Mentis Cura). An analysis of the cholinergic index is not revealed to the clinician that is thus blinded to this part of the EEG analysis.
The project will be analysed based on all available information after primary end point. A second analysis will be performed after the second end point.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Mild Cognitive Impairment or mild dementia due to Alzheimer´s disease or with dementia due to Lewy body disease.
Exclusion Criteria:
- Too advanced dementia (5 or more on Global Deterioration Scale)
- likelihood of poor compliance due to social circumstances, drug or alcohol abuse or other defined causes.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
MCI due to Alzheimer´s disease
Individuals with MCI diagnosed with Alzheimer´s disease on the basis of cognitive decline and positive biomarkers by MRI and/or Cerebro Spinal Fluid (CSF) analysis.
The intervention is donepezil in recommended doses, 5mg/day for a month and then 10mg/day.
Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
|
Mild dementia due to Alzheimer´s disease
Individuals with mild dementia and diagnosed with Alzheimer´s disease on the basis of cognitive decline and positive biomarkers by MRI and/or CSF analysis.
The intervention is donepezil in recommended doses, 5mg/day for a month and then 10mg/day.
Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
|
Mild dementia due to Lewy body disease
Individuals with mild Lewy body dementia.
The intervention is Exelon patches in recommended doses, 4.6mg/day for a month and then 9.5mg/day.
Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in Addenbrooke cognitive battery at 3 months and at 6 months
Time Frame: Baseline, 3 months, 6 months
|
Addenbrooke cognitive battery will be used before initiating treatment (baseline), after 3 months and after 6 months
|
Baseline, 3 months, 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mini Mental State Examination (MMSE)
Time Frame: Baseline, 3 months, 6 months
|
MMSE will be used before initiating treatment (baseline), after 3 months and after 6 months
|
Baseline, 3 months, 6 months
|
CERAD-10 word test
Time Frame: Baseline, 3 months, 6 months
|
CERAD-10 word test will be used before initiating treatment (baseline) after 3 months and 6 months
|
Baseline, 3 months, 6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jon Snaedal, MD, Professor
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LSH-15-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer´s Disease
-
Baxalta now part of ShireTerminatedAlzheimer´s DiseaseUnited States, Poland, United Kingdom, Belgium, Spain, Japan, Canada, Australia
-
Affiris AGTerminatedAlzheimer´s DiseaseFrance, Austria, Croatia, Czech Republic, Germany, Slovakia
-
AstraZenecaTerminatedAlzheimer´s DiseaseRussian Federation, Ukraine
-
University of WuerzburgCompletedAlzheimer´s DiseaseGermany
-
Baxalta now part of ShireTerminated
-
Affiris AGTerminatedAlzheimer´s DiseaseAustria
-
JSW LifesciencesTerminated
-
Noscira SACompletedAlzheimer´s DiseaseGermany
-
University Hospital, SaarlandUniversity of Goettingen, Section Neurobiology (Head: Prof. Dr. T. Bayer)...CompletedAlzheimer´s Disease